Ravenna Becomes the First Colourblind-Friendly City in Italy: Event and New EnChroma Glasses Donation
18.3.2025 17:29:00 CET | Business Wire | Press Release
Tomorrow, March 19, 2025, at 4:30 PM, the conference "How Colourblind People See" will be held at the Martini Hall of MAR – Ravenna’s Museum of Art. This event is dedicated to raising awareness about colour blindness and the challenges of colour perception. Speakers will include Stefano De Pietro, President of the Italian Association "How Colourblind People See", and Sandor Breznay, President of the Breznay-Ganoczy Foundation (Agno, Switzerland) and the Paolina Brugnatelli Foundation (Milan).
Colour blindness affects approximately 1 in 12 men and 1 in 200 women, with over 300 million people worldwide experiencing this condition—2.5 million in Italy. While those with normal colour vision can distinguish over a million shades, individuals with colour vision deficiency see only about 10% of those hues. As a result, colours may appear dull or even indistinguishable. This initiative aims to increase public awareness and make cultural and educational experiences more accessible for those with colour blindness.
The event, promoted by the Rotary Club Ravenna and Lions Club Ravenna Host, represents another step forward in Ravenna’s commitment to perceptual inclusivity. During the conference, the Rotary Club will donate a set of EnChroma colourblind glasses to MAR, allowing colourblind visitors to borrow them for a more inclusive visual experience. Additionally, the Lions Club Ravenna Host will donate another set of glasses to the Nervi-Severini Art High School, integrating colour blindness awareness into art and education.
The event is organized in collaboration with the Rotary Club Ravenna, Lions Club Ravenna Host, and the Academy of Fine Arts of Ravenna (ABA).
This initiative is part of a broader project that establishes Ravenna as the first Italian city accessible to colourblind individuals. Last summer, several UNESCO sites in Ravenna, famous for their extraordinary mosaics, began offering EnChroma glasses to visitors, allowing them to perceive the vibrant colours of the artwork more accurately.
A standout effort in this movement is the "ColoRaMi" project, launched by Ravenna Mosaici, which provides colourblind visitors with EnChroma glasses to experience the city’s stunning mosaics more colourfully. This project includes major UNESCO monuments such as the Basilica di San Vitale, il Mausoleo di Galla Placidia, la Basilica di Sant'Apollinare Nuovo e il Battistero Neoniano. This initiative ensures that Ravenna’s artistic heritage is accessible to an even wider audience. More details on the project can be found here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250318458916/en/
Contacts
For More Information:
Paolina Brugnatelli Foundation
+39 3428234246
info@fondazionepaolinabrugnatelli.org
EnChroma
Cecilia Gerosa – Marketing and PR Manager
+39 3387854590
cecilia@enchroma.co.uk
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom